Grade-dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis Journal Article


Authors: Wettersten, H. I.; Hakimi, A. A.; Morin, D.; Bianchi, C.; Johnstone, M.; Donohoe, D. R.; Trott, J. F.; Abu Aboud, O.; Stirdivant, S.; Neri, B.; Wolfert, R.; Stewart, B.; Perego, R.; Hsieh, J. J.; Weiss, R. H.
Article Title: Grade-dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis
Abstract: Kidney cancer [or renal cell carcinoma (RCC)] is known as "the internist's tumor" because it has protean systemic manifestations, suggesting that it utilizes complex, nonphysiologic metabolic pathways. Given the increasing incidence of this cancer and its lack of effective therapeutic targets, we undertook an extensive analysis of human RCC tissue employing combined grade-dependent proteomics and metabolomics analysis to determine how metabolic reprogramming occurring in this disease allows it to escape available therapeutic approaches. After validation experiments in RCC cell lines that were wild-type or mutant for the Von Hippel-Lindau tumor suppressor, in characterizing higher-grade tumors, we found that the Warburg effect is relatively more prominent at the expense of the tricarboxylic acid cycle and oxidative metabolism in general. Further, we found that the glutamine metabolism pathway acts to inhibit reactive oxygen species, as evidenced by an upregulated glutathione pathway, whereas the beta-oxidation pathway is inhibited, leading to increased fatty acylcarnitines. In support of findings from previous urine metabolomics analyses, we also documented tryptophan catabolism associated with immune suppression, which was highly represented in RCC compared with other metabolic pathways. Together, our results offer a rationale to evaluate novel antimetabolic treatment strategies being developed in other disease settings as therapeutic strategies in RCC. (C) 2015 AACR.
Keywords: oxidation; identification; cells; mass-spectrometry
Journal Title: Cancer Research
Volume: 75
Issue: 12
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 2015-06-15
Start Page: 2541
End Page: 2552
Language: English
ACCESSION: WOS:000357334400015
DOI: 10.1158/0008-5472.can-14-1703
PROVIDER: wos
PMCID: PMC4470795
PUBMED: 25952651
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. James J Hsieh
    125 Hsieh
  2. Abraham Ari Hakimi
    324 Hakimi